Acquisition by Michael Richman of 5165 shares of Pieris Pharmaceuticals subject to Rule 16b-3
| PIRSDelisted Stock | USD 13.60 1.41 9.39% |
Slightly above 62% of Pieris Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Pieris Pharmaceuticals suggests that many traders are alarmed. Pieris Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Pieris Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Pieris |
Filed transaction by Pieris Pharmaceuticals In director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Pieris Pharmaceuticals Fundamental Analysis
We analyze Pieris Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pieris Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pieris Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Pieris Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Pieris Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pieris Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Pieris Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Pieris Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Pieris Pharmaceuticals Related Equities
| ADCT | ADC Therapeutics | 10.99 | ||||
| CRVS | Corvus Pharmaceuticals | 8.30 | ||||
| TERN | Terns Pharmaceuticals | 5.03 | ||||
| INZY | Inozyme Pharma | 1.81 | ||||
| AGEN | Agenus | 1.47 | ||||
| MREO | Mereo BioPharma | 0.60 | ||||
| ADAP | Adaptimmune Therapeutics | 1.64 | ||||
| ACHL | Achilles Therapeutics | 2.02 | ||||
| PDSB | PDS Biotechnology | 3.31 | ||||
| LPTX | Leap Therapeutics | 4.14 | ||||
| CUE | Cue Biopharma | 4.67 | ||||
| XFOR | X4 Pharmaceuticals | 4.69 | ||||
| CKPT | Checkpoint Therapeutics | 5.60 | ||||
| AFMD | Affimed NV | 6.35 |
Check out Pieris Pharmaceuticals Hype Analysis, Pieris Pharmaceuticals Correlation and Pieris Pharmaceuticals Performance. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Pieris Stock
If you are still planning to invest in Pieris Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pieris Pharmaceuticals' history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |